Future perspectives for the treatment of pulmonary arterial hypertension
Hossein A Ghofrani, Robyn J Barst, Raymond L Benza, Hunter C Champion, Karen A Fagan, Friedrich Grimminger, Marc Humbert, Gérald Simonneau, Duncan J Stewart, Carlo Ventura, Lewis J Rubin, Hossein A Ghofrani, Robyn J Barst, Raymond L Benza, Hunter C Champion, Karen A Fagan, Friedrich Grimminger, Marc Humbert, Gérald Simonneau, Duncan J Stewart, Carlo Ventura, Lewis J Rubin
Abstract
Over the past 2 decades, pulmonary arterial hypertension has evolved from a uniformly fatal condition to a chronic, manageable disease in many cases, the result of unparalleled development of new therapies and advances in early diagnosis. However, none of the currently available therapies is curative, so the search for new treatment strategies continues. With a deeper understanding of the genetics and the molecular mechanisms of pulmonary vascular disorders, we are now at the threshold of entering a new therapeutic era. Our working group addressed what can be expected in the near future. The topics span the understanding of genetic variations, novel antiproliferative treatments, the role of stem cells, the right ventricle as a therapeutic target, and strategies and challenges for the translation of novel experimental findings into clinical practice.
Conflict of interest statement
Conflicts of Interest:
Dr. Barst has received honoraria for serving as a consultant, advisory board member, and/or speaker from Actelion Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Gilead Sciences, Novartis, and Pfizer.
Dr. Benza has received grant support from Actelion Pharmaceuticals, Gilead Sciences, LungRx, and United Therapeutics; and speaking honoraria from Actelion, Gilead, and United Therapeutics.
Dr. Champion has indicated no conflict of interest to disclose.
Dr. Fagan TK
Dr. Ghofrani has received honoraria and research funds from Actelion Pharmaceuticals, Bayer Schering, Encysive Pharmaceuticals, ErgoNex Pharma, GlaxoSmithKline, Novartis, and Pfizer.
Dr. Grimminger has received honoraria and research funds from Actelion Pharmaceuticals, Bayer Schering, Novartis, and Pfizer.
Dr. Humbert has received honoraria and research grants from Actelion Pharmaceuticals, Bayer Schering, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics.
Dr. Rubin has received research grants from Actelion Pharmaceuticals, Gilead Sciences, the National Heart, Lung and Blood Institute, Pfizer, and United Therapeutics; and has served on advisory committees for Actelion, Gilead, and Pfizer; and as a consultant for Actelion, Aires Pharmaceuticals, Bayer Schering Pharma, Cerulean Biosciences, Gilead, mondoBIOTECH, the National Heart, Lung and Blood Institute, Onyx Pharmaceuticals, Pfizer, Solvay Pharmaceuticals, and United Therapeutics. He owns stock in United Therapeutics.
Prof. Simonneau has received honoraria and research grants from Actelion Pharmaceuticals, Bayer Schering, GlaxoSmithKline, Pfizer, and United Therapeutics.
Dr. Stewart has received honoraria from Lung Rx and is a shareholder in Northern Therapeutics.
Dr. Ventura has received funds from “Regione Emilia Romagna, Italy.”
Source: PubMed